Wells Fargo & Company Initiates Coverage on LeMaitre Vascular (NASDAQ:LMAT)

Equities researchers at Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular (NASDAQ:LMAT) in a research report issued to clients and investors on Thursday,Briefing.com Automated Import reports. The brokerage set an “equal weight” rating and a $95.00 price target on the medical instruments supplier’s stock. Wells Fargo & Company‘s price target would indicate a potential downside of 1.37% from the stock’s current price.

A number of other research firms also recently weighed in on LMAT. Barrington Research raised their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Finally, Oppenheimer reiterated an “outperform” rating and set a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $94.63.

LeMaitre Vascular Stock Performance

NASDAQ LMAT opened at $96.32 on Thursday. The stock has a market capitalization of $2.17 billion, a price-to-earnings ratio of 52.63, a PEG ratio of 2.19 and a beta of 0.96. LeMaitre Vascular has a 52 week low of $58.66 and a 52 week high of $109.58. The stock’s 50 day moving average price is $96.27 and its two-hundred day moving average price is $93.45.

Insider Buying and Selling

In other news, Director Bridget A. Ross sold 3,750 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the sale, the director now directly owns 2,278 shares of the company’s stock, valued at $231,148.66. This trade represents a 62.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 10.79% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Raymond James Financial Inc. bought a new position in LeMaitre Vascular during the fourth quarter worth $14,900,000. Segall Bryant & Hamill LLC acquired a new stake in shares of LeMaitre Vascular during the 4th quarter worth about $5,446,000. DF Dent & Co. Inc. boosted its holdings in shares of LeMaitre Vascular by 26.2% during the 3rd quarter. DF Dent & Co. Inc. now owns 258,767 shares of the medical instruments supplier’s stock worth $24,037,000 after buying an additional 53,797 shares during the period. JPMorgan Chase & Co. grew its stake in LeMaitre Vascular by 45.9% in the 4th quarter. JPMorgan Chase & Co. now owns 147,489 shares of the medical instruments supplier’s stock valued at $13,590,000 after buying an additional 46,430 shares during the last quarter. Finally, Conestoga Capital Advisors LLC raised its holdings in LeMaitre Vascular by 1.9% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier’s stock valued at $183,769,000 after acquiring an additional 36,850 shares during the period. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.